# Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

> **NCT00191295** · PHASE2,PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 240 (—)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00191295
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 240 (—)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191295, "Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00191295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*